Anthony T. Reder

10.7k total citations · 1 hit paper
160 papers, 7.3k citations indexed

About

Anthony T. Reder is a scholar working on Pathology and Forensic Medicine, Oncology and Immunology. According to data from OpenAlex, Anthony T. Reder has authored 160 papers receiving a total of 7.3k indexed citations (citations by other indexed papers that have themselves been cited), including 106 papers in Pathology and Forensic Medicine, 51 papers in Oncology and 49 papers in Immunology. Recurrent topics in Anthony T. Reder's work include Multiple Sclerosis Research Studies (105 papers), Cytokine Signaling Pathways and Interactions (30 papers) and Immunotherapy and Immune Responses (25 papers). Anthony T. Reder is often cited by papers focused on Multiple Sclerosis Research Studies (105 papers), Cytokine Signaling Pathways and Interactions (30 papers) and Immunotherapy and Immune Responses (25 papers). Anthony T. Reder collaborates with scholars based in United States, Canada and Switzerland. Anthony T. Reder's co-authors include Barry G.W. Arnason, Jack P. Antel, Mark Rametta, Susan A. Gregory, Davide Maimone, Douglas S. Goodin, Xuan Feng, Ludwig Kappos, Kürşad Genç and Dawn Langdon and has published in prestigious journals such as Science, Journal of Clinical Investigation and The Journal of Immunology.

In The Last Decade

Anthony T. Reder

154 papers receiving 7.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

2014 664 citations Peter A. Calabresi, Douglas S. Goodin et al. profile →

Peers

Anthony T. Reder

PFM

IMMUN

NEURO

ONCOL

Pierre Duquette Canada

Uwe K. Zettl Germany

S. Fredrikson Sweden

Rogier Q. Hintzen Netherlands

Manuel Comabella Spain

John Rose United States

Timothy Vollmer United States

Paolo Gallo Italy

Tania Kümpfel Germany

Jan Lycke Sweden

Pierre Duquette Canada

Anthony T. Reder

4.1k ×0.9

PFM

2.4k ×1.3

IMMUN

1.4k ×0.9

NEURO

860 ×0.6

1.0k ×0.8

ONCOL

Citations per year, relative to Anthony T. Reder Anthony T. Reder (= 1×) peers Pierre Duquette

Countries citing papers authored by Anthony T. Reder

Since Specialization

Citations

This map shows the geographic impact of Anthony T. Reder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anthony T. Reder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anthony T. Reder more than expected).

Fields of papers citing papers by Anthony T. Reder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anthony T. Reder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anthony T. Reder. The network helps show where Anthony T. Reder may publish in the future.

Co-authorship network of co-authors of Anthony T. Reder

This figure shows the co-authorship network connecting the top 25 collaborators of Anthony T. Reder. A scholar is included among the top collaborators of Anthony T. Reder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anthony T. Reder. Anthony T. Reder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Reder, Anthony T.. (2025). Two roads diverged in multiple sclerosis: When is switching therapy effective?. Neurotherapeutics. 22(6). e00734–e00734.

Reder, Anthony T., et al.. (2024). Alternative Splicing of RNA Is Excessive in Multiple Sclerosis and Not Linked to Gene Expression Levels: Dysregulation Is Corrected by IFN-β. Journal of Interferon & Cytokine Research. 44(8). 355–371. 2 indexed citations

Freedman, Mark S., Patricia K. Coyle, Kerstin Hellwig, et al.. (2024). Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives. Neurology and Therapy. 13(2). 283–322. 4 indexed citations

Spencer, Julian T., et al.. (2023). Adaptive and innate immune responses in multiple sclerosis with anti-CD20 therapy: Gene expression and protein profiles. Frontiers in Neurology. 14. 1158487–1158487. 4 indexed citations

Williams, Mitzi, Anne H. Cross, Nancy Monson, et al.. (2023). Demographics and baseline disease characteristics of Black and Hispanic patients with multiple sclerosis in the open-label, single-arm, multicenter, phase IV CHIMES trial. Multiple Sclerosis and Related Disorders. 76. 104794–104794. 8 indexed citations

Feng, Xuan, et al.. (2023). Prolonged Interferon-Stimulated Gene and Protein Signatures in Multiple Sclerosis Induced by PEGylated IFN-β-1a Compared to Non-PEGylated IFN-β-1a. Journal of Interferon & Cytokine Research. 43(3). 108–120. 4 indexed citations

Amezcua, Lilyana, Anne H. Cross, Nancy Monson, et al.. (2022). Demographics and Baseline Disease Characteristics of Black and Hispanic Patients With Multiple Sclerosis in the CHIMES Trial (P4-4.005). Neurology. 98(18_supplement). 1 indexed citations

Reder, Anthony T., Diego Centonze, Maria L. Naylor, et al.. (2021). COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies. CNS Drugs. 35(3). 317–330. 85 indexed citations

Weinstock‐Guttman, Bianca, Robert A Bermel, Gary Cutter, et al.. (2021). Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial. Multiple Sclerosis Journal. 28(5). 790–800. 16 indexed citations

10.

Cohan, Stanley, Barry Hendin, Anthony T. Reder, et al.. (2021). Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex). CNS Drugs. 35(7). 743–767. 1 indexed citations

11.

Reder, Anthony T., et al.. (2021). Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders. 51. 102935–102935. 4 indexed citations

12.

Lukas, Rimas V., Naoum P. Issa, Adil Javed, et al.. (2018). Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsy. Epilepsy & Behavior. 80. 331–336. 73 indexed citations

13.

Poulos, Christine, et al.. (2015). Patient Preferences for Injectable Treatments for Multiple Sclerosis in the United States: A Discrete-Choice Experiment. Patient. 9(2). 171–180. 37 indexed citations

14.

Reder, Anthony T. & Xuan Feng. (2014). How Type I Interferons Work in Multiple Sclerosis and Other Diseases: Some Unexpected Mechanisms. Journal of Interferon & Cytokine Research. 34(8). 589–599. 60 indexed citations

15.

Yu, Lijian, Ed Croze, Ken Yamaguchi, et al.. (2014). Induction of a Unique Isoform of the NCOA7 Oxidation Resistance Gene by Interferon β-1b. Journal of Interferon & Cytokine Research. 35(3). 186–199. 33 indexed citations

16.

Goodin, Douglas S., Douglas Jeffery, Ludwig Kappos, et al.. (2013). Fingolimod Reduces Annualized Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis: FREEDOMS II Study Subgroup Analysis (P07.102). Neurology. 80(7_supplement). 4 indexed citations

17.

Goodin, Douglas S., George C. Ebers, Gary Cutter, et al.. (2012). Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study. BMJ Open. 2(6). e001972–e001972. 38 indexed citations

18.

Reder, Anthony T., Sharlene Velichko, Ken Yamaguchi, et al.. (2008). IFN- β 1b Induces Transient and Variable Gene Expression in Relapsing-Remitting Multiple Sclerosis Patients Independent of Neutralizing Antibodies or Changes in IFN Receptor RNA Expression. Journal of Interferon & Cytokine Research. 28(5). 317–331. 40 indexed citations

19.

Feng, Xuan, Douglas M. Yau, Christopher Holbrook, & Anthony T. Reder. (2002). Type I Interferons Inhibit Interleukin-10 Production in Activated Human Monocytes and Stimulate IL-10 in T Cells: Implications for Th1-Mediated Diseases. Journal of Interferon & Cytokine Research. 22(3). 311–319. 28 indexed citations

20.

Reder, Anthony T. & Martin T. Lowy. (1992). Interferon-β Treatment Does Not Elevate Cortisol in Multiple Sclerosis. Journal of Interferon Research. 12(3). 195–198. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact